News Related to NG Biotech

Related coverage linked through entity extraction aliases.

FDA grants breakthrough designation to two rapid tests for drug-resistant pathogens

Apr 17, 2026

The FDA granted Breakthrough Device Designations to NG-TEST® Candida auris and NG-TEST® Acineto-5®, two rapid assays targeting critical drug-resistant pathogens. Both tests deliver results within 15 minutes and are currently available for Research Use Only while FDA review continues.

FDA Grants Breakthrough Device Status to Rapid Tests for Drug-Resistant Pathogens

Feb 28, 2026

The FDA has granted breakthrough device designation to two rapid diagnostic assays from NG Biotech and Hardy Diagnostics targeting Candida auris and carbapenem-resistant Acinetobacter baumannii, both identified as global health priorities by the WHO.